GlassScriptPhysician profile
Erin M Bertino
NPI 1043355688
$72,687.85
in general payments reported to CMS, 2019-2025
18 companies · $8,660 in 2025
The $8,660 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,558 · 2021: $12K · 2022: $4,115 · 2023: $18K · 2024: $15K · 2025: $8,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $9,521 · Travel and Lodging: $3,716 · Food and Beverage: $656 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,613.75 |
| Consulting Fee | $9,521.00 |
| Travel and Lodging | $3,715.82 |
| Food and Beverage | $656.49 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44,620.78 | 2019-2025 | |
| Genzyme Corporation | $17,933.59 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $2,050.00 | 2025 | Tagrisso |
| Janssen Biotech, INC. | $1,691.12 | 2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $1,625.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $1,590.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $1,568.00 | 2024 | Libtayo |
| Array Biopharma INC | $700.00 | 2024 | Braftovi |
| Novocure INC. | $570.80 | 2021 | |
| Genentech USA, INC. | $170.67 | 2023-2025 | Lunsumio |
| Tempus Ai, INC | $78.08 | 2024 | |
| Novartis Pharmaceuticals Corporation | $74.18 | 2021 | |
| Amgen INC. | $15.63 | 2023 | Lumakras |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Bertino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.